Valuation: Genmab A/S

Market Cap 113B 17.31B 15.17B 14.02B 12.9B 24.33B 1,669B 24.72B 168B 65.72B 817B 64.98B 63.57B 2,813B P/E 2026 *
24.1x
P/E 2027 * 16.8x
Enterprise Value 133B 20.26B 17.76B 16.41B 15.09B 28.48B 1,953B 28.94B 196B 76.93B 956B 76.07B 74.41B 3,293B EV / Sales 2026 *
4.73x
EV / Sales 2027 * 3.79x
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
1 day-0.35%
1 week-1.10%
Current month+2.48%
1 month+11.11%
3 months+6.21%
6 months-11.90%
Current year-9.25%
1 week 1,823.5
Extreme 1823.5
1,907
1 month 1,620.5
Extreme 1620.5
1,933
Current year 1,512
Extreme 1512
2,257
1 year 1,337
Extreme 1337
2,257
3 years 1,157
Extreme 1157
2,814
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Date Insider Type Main position Quantity % Market Cap.
01/12/25 Fiscal year

Director

189 0.0003%
01/12/25 Fiscal year

Director

189 0.0003%
01/12/25 Fiscal year

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%-1.10%+32.20%-33.93% 17.31B
+0.32%-0.68%+56.52%+53.72% 53.79B
+5.37%+3.31%+50.39%+83.65% 54.69B
-1.20%-1.94%+4.35%+402.68% 23.2B
+0.74%+2.32%-16.23%-14.44% 23.31B
+1.46%+1.62%+38.64%-4.62% 20.03B
-1.67%-6.00%+163.95%+284.69% 14.99B
+1.49%+2.67%+35.46%+586.58% 15.36B
-0.70%-0.91%+24.87%+179.47% 13.96B
-3.21%+0.88%+60.32%+151.29% 12.35B
Average +0.23%-0.55%+45.05%+168.91% 24.9B
Weighted average by Cap. +1.09%-0.84%+43.96%+134.32%

Financials

2026 *2027 *
Net sales 28.06B 4.28B 3.75B 3.47B 3.19B 6.02B 413B 6.12B 41.49B 16.27B 202B 16.08B 15.73B 696B 33.02B 5.04B 4.42B 4.08B 3.76B 7.09B 486B 7.2B 48.82B 19.14B 238B 18.92B 18.51B 819B
Net income 4.76B 726M 636M 588M 541M 1.02B 70B 1.04B 7.03B 2.76B 34.25B 2.73B 2.67B 118B 7.08B 1.08B 947M 876M 805M 1.52B 104B 1.54B 10.47B 4.11B 51B 4.06B 3.97B 176B
Net Debt 19.34B 2.95B 2.59B 2.39B 2.2B 4.15B 285B 4.22B 28.59B 11.21B 139B 11.08B 10.84B 480B 11.8B 1.8B 1.58B 1.46B 1.34B 2.53B 174B 2.57B 17.44B 6.84B 84.96B 6.76B 6.61B 293B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,088
Date Price Change Volume
21/07/26 DKK 1,838.50 -0.46% 15,366
20/07/26 DKK 1,847.00 -1.18% 100,442
17/07/26 DKK 1,869.00 -1.14% 149,830
16/07/26 DKK 1,890.50 -0.29% 110,603
15/07/26 DKK 1,896.00 +1.94% 139,112
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
1,847.00DKK
Average target price
2,333.28DKK
Spread / Average Target
+26.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock